2016 American Society of Clinical Oncology Annual Meeting*

Download All
June 3-7, 2016; Chicago, Illinois
Bradley Monk, MD, selects the most important presentations on gynecologic cancers from the 2016 American Society of Clinical Oncology Annual Meeting.

Gynecologic Cancers

5-year follow-up of Study 19 to determine if olaparib maintenance monotherapy maintained a survival advantage over placebo in patients with BRCA-mutated platinum-sensitive ovarian cancer.

Released: June 8, 2016

Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.

Released: June 9, 2016

Prior bevacizumab did not adversely affect efficacy or safety of subsequent bevacizumab retreatment in recurrent platinum-sensitive ovarian cancer.

Released: June 6, 2016

IP carboplatin shows substantial reduction in PD rates at 9 months vs IV chemotherapy with similar tolerability.

Released: June 9, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Merck & Co., Inc.
Taiho Pharmaceuticals

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings